Soligenix Expanded Its Phase 2A Trial Of SGX302 (Synthetic Hypericin) For Mild-To-Moderate Psoriasis After Demonstrating Biological Effect In The Initial Five Subjects; The Study Is Expected To Enroll At Least An Additional Five Subjects
Portfolio Pulse from Benzinga Newsdesk
Soligenix has expanded its Phase 2A trial of SGX302, a synthetic hypericin, for mild-to-moderate psoriasis after demonstrating a biological effect in the initial five subjects. The study is expected to enroll at least an additional five subjects.
July 11, 2023 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Soligenix's expansion of its Phase 2A trial of SGX302 indicates positive initial results, which could potentially boost investor confidence in the company.
The expansion of the Phase 2A trial of SGX302 by Soligenix indicates that the initial results were positive. This could potentially boost investor confidence in the company and its product, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100